ROCKVILLE, Md., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the following investor conferences:
| Stifel 2015 Healthcare Conference |
| Presentation Date: Tuesday, November 17th |
| Presentation Time: 4:30 PM ET |
| Place: The New York Palace Hotel, New York |
| Piper Jaffray 27th Annual Healthcare Conference |
| Presentation Date: Tuesday, December 1st |
| Presentation Time: 10:30 AM ET |
| Place: The New York Palace Hotel, New York |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinator.
A live webcast of the presentations can be accessed by visiting 'Events & Presentations' in the Investors Section on the Company's website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company's website following the conferences.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment, and SPN-812 for ADHD.